Berberine protects against diabetic kidney disease via promoting PGC-1α-regulated mitochondrial energy homeostasis.

Clicks: 461
ID: 65961
2019
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Emerging

Ranked #2 of 36 articles by views in british journal of pharmacology

Most read Least read

Bar heights use a square-root scale.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
Lipid metabolism disorder and disturbed mitochondrial bioenergetics play pivotal roles in the occurrence and development of diabetic kidney disease (DKD). Berberine (BBR) is a kind of alkaloid derived from Chinese herbal medicine. It has multiple therapeutic actions on diabetes mellitus and its complications, including regulation of glucose and lipid metabolism, improvement of insulin sensitivity and alleviation of oxidative damage. Here we investigated the renoprotective effects of BBR.Combined clinical study in DKD patients with experimental studies in diabetic mice and cultured podocytes, we characterized the energy metabolism profiles based on metabolomics, investigated molecular targets and mechanisms of BBR at regulating mitochondrial function and bioenergetics, and testified the effects of BBR on metabolic alterations in DKD animal model.Metabolomics examination suggested altered mitochondrial fuel usage and generalized mitochondrial dysfunction in DKD patients. BBR intervention potently reversed metabolic disorders, podocyte damage and glomerulosclerosis in db/db mice. Lipid accumulation, excessive generation of mitochondrial reactive oxygen species, mitochondrial dysfunction and insufficient fatty acids oxidation in DKD mouse models and cultured podocytes were significantly suppressed by BBR. The protective mechanism of BBR might involve the activation of peroxisome proliferator-activated receptor γ coactivator-1α (PGC-1α) signaling pathway, thereby promoting mitochondrial energy homeostasis and fatty acid oxidation in podocytes.Our research elucidated that PGC-1α-mediated mitochondrial bioenergetics might play a key role in lipid disorder-induced podocyte damage and development of DKD. Restoration of PGC-1α activity and the energy homeostasis by BBR might be a potential therapeutic strategy against DKD.
Reference Key
qin2019berberinebritish Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Qin, Xin;Jiang, Ming;Zhao, Yan;Gong, Jing;Su, Hao;Yuan, Fen;Fang, Ke;Yuan, Xiaoyi;Yu, Xiao;Dong, Hui;Lu, Fuer;
Journal british journal of pharmacology
Year 2019
DOI
10.1111/bph.14935
URL
Keywords
pgc-1α berberine diabetic kidney diseases fatty acids oxidation mitochondrial bioenergetics

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.